Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus/Eucreas) and Sitagliptin (Januvia/Janumet) After Two Weeks.

Trial Profile

Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus/Eucreas) and Sitagliptin (Januvia/Janumet) After Two Weeks.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Vildagliptin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms FPG-VISIT
  • Sponsors Novartis; Novartis Pharma
  • Most Recent Events

    • 19 Sep 2014 Primary endpoint has been met (Fasting plasma glucose level after 14 days of treatment with vildagliptin is superior to sitagliptin), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top